Roth Capital set a $47.00 price target on Global Blood Therapeutics Inc. (NASDAQ:GBT) in a report published on Monday. The firm currently has a buy rating on the stock.

GBT has been the topic of several other research reports. Zacks Investment Research upgraded Global Blood Therapeutics from a hold rating to a buy rating and set a $20.00 price target on the stock in a research note on Tuesday, October 11th. Wedbush reiterated an outperform rating and set a $66.00 target price on shares of Global Blood Therapeutics in a research note on Monday, August 22nd. Wells Fargo & Co. began coverage on Global Blood Therapeutics in a research note on Friday, September 30th. They set an outperform rating and a $23.05 target price on the stock. Cowen and Company reiterated an outperform rating and set a $83.00 target price (up from $80.00) on shares of Global Blood Therapeutics in a research note on Wednesday, October 26th. Finally, Morgan Stanley reiterated a buy rating and set a $62.00 target price on shares of Global Blood Therapeutics in a research note on Sunday, August 14th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus target price of $47.86.

Global Blood Therapeutics (NASDAQ:GBT) last posted its quarterly earnings results on Wednesday, November 9th. The company reported ($0.58) earnings per share for the quarter, hitting the consensus estimate of ($0.58). During the same period in the previous year, the company posted ($0.90) earnings per share.

ILLEGAL ACTIVITY WARNING: This report was posted by Daily Political and is the propert of of Daily Political. If you are viewing this report on another website, it was copied illegally and republished in violation of US and international copyright & trademark law. The original version of this report can be accessed at http://www.dailypolitical.com/2016/12/01/roth-capital-analysts-give-global-blood-therapeutics-inc-gbt-a-47-00-price-target.html.

Several institutional investors have recently added to or reduced their stakes in the company. Nationwide Fund Advisors increased its position in Global Blood Therapeutics by 101.7% in the second quarter. Nationwide Fund Advisors now owns 9,100 shares of the company’s stock worth $151,000 after buying an additional 4,588 shares during the period. GSA Capital Partners LLP purchased a new position in Global Blood Therapeutics during the second quarter worth about $181,000. Fernwood Investment Management LLC increased its position in Global Blood Therapeutics by 100.0% in the second quarter. Fernwood Investment Management LLC now owns 39,900 shares of the company’s stock worth $662,000 after buying an additional 19,950 shares during the period. DIAM Co. Ltd. increased its position in Global Blood Therapeutics by 59.7% in the second quarter. DIAM Co. Ltd. now owns 143,191 shares of the company’s stock worth $2,305,000 after buying an additional 53,532 shares during the period. Finally, Swiss National Bank increased its position in Global Blood Therapeutics by 124.8% in the second quarter. Swiss National Bank now owns 28,100 shares of the company’s stock worth $466,000 after buying an additional 15,600 shares during the period. Hedge funds and other institutional investors own 56.01% of the company’s stock.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company’s segment is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders.

5 Day Chart for NASDAQ:GBT

Receive News & Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.